Skip to content

Fiona Measham

7 papers in the library · 147 citations · publishing 2009-2022

Papers

Sort Most recent Most cited

Size matters: comparing the MDMA content and weight of ecstasy tablets submitted to European drug checking services in 2012–2021

Drugs, Habits and Social Policy November 24, 2022 Ruben Q Vrolijk, Fiona Measham, Adrià Quesada et al.

Purpose The 3,4-methylenedioxymetamphetamine (MDMA) content in ecstasy tablets has increased enormously throughout Europe across the past decade. This study aims to determine whether this is caused by the production of “stronger” tablets (more mg MDMA per mg of tablet), or if tablets have simply been getting larger and heavier (more mg of tablet in total). Design/methodology/approach A data set...

Cannabis adulterated with the synthetic cannabinoid receptor agonist MDMB-4en-PINACA and the role of European drug checking services.

International Journal of Drug Policy February 2022 Pieter E Oomen, Dominique Schori, Karsten Tögel-Lins et al.

European drug checking services exchange information on drug trends within the Trans European Drug Information (TEDI) network, allowing monitoring and coordination of responses. Starting in Spring 2020, several services detected the synthetic cannabinoid receptor agonist MDMB-4en-PINACA in adulterated low-THC cannabis products. Cannabis products suspected of adulteration were analyzed for the...

Debunking the myth of 'Blue Mondays': No evidence of affect drop after taking clinical MDMA.

Journal of Psychopharmacology December 13, 2021 Ben Sessa, Jacob S. Aday, Steve O’Brien et al. 18 citations

BACKGROUND: Incorporating 3,4-methylenedioxymethamphetamine (MDMA) as an adjunct to psychotherapy has shown promise in recent years for treating various mental health conditions, particularly those involving trauma. However, concerns about declines in mood and cognition during the days following dosing, also known as 'Blue Mondays', have been raised as limitations to its clinical use. Although...

DOI: 10.1177/02698811211055809 (opens in new tab) Ecstasy Molly 3 4-methylenedioxymethamphetamine +16

City Checking: Piloting the UK's first community-based drug safety testing ('drug checking') service in two city centres.

British Journal of Clinical Pharmacology February 6, 2020 Fiona Measham

AIMS To explore the feasibility of delivering community-based drug safety testing ('drug checking'), to trial service design characteristics and to compare with festival-based testing. METHODS 171 substances of concern were submitted on five dates at three venues in two UK cities and tested using up to six analytical techniques. Test results and harm reduction advice were distributed directly...

Salvia divinorum use and phenomenology: results from an online survey.

Journal of Psychopharmacology November 1, 2011 Harry Sumnall, Fiona Measham, Simon D. Brandt et al. 38 citations

Salvia divinorum is a hallucinogenic plant with ethnopharmacological and recreational uses. It differs from classic serotonergic hallucinogens such as LSD and psilocin in both phenomenology and potent agonist activity of the active component salvinorin A at κ-opioid receptors. Awareness of S. divinorum has grown recently, with both an increase in its public representation and concern over its...

DOI: 10.1177/0269881110385596 (opens in new tab) Full text (opens in new tab) Salvia divinorum Hallucinogenic plant Psychoactive plant User experiences +15

The confusing case of NRG-1

BMJ July 6, 2010 Simon D. Brandt, Harry Sumnall, Fiona Measham et al. 57 citations

Since the recent ban on mephedrone,1 2several alternative products have been introduced on internet websites. One of the most prominently discussed second generation products is Energy 1 (NRG-1), also advertised as naphyrone (naphthylpyrovalerone, O-2482), which originated from a group of compounds previously described in the medicinal chemistry …

DOI: 10.1136/bmj.c3564 (opens in new tab) Mephedrone The internet Internet privacy World wide web +1

MDMA powder, pills and crystal: the persistence of ecstasy and the poverty of policy

Drugs and Alcohol Today April 13, 2009 Zoe R. Smith, Karenza Moore, Fiona Measham 34 citations

Commonly known as ecstasy, MDMA has been central to the British acid house, rave and dance club scene over the last 20 years. Figures from the annual national British Crime Survey suggest that ecstasy use has declined since 2001. This apparent decline is considered here alongside the concurrent emergence of a ‘new’ form of ecstasy ‐ MDMA powder or crystal ‐ and the extent to which this can be...

DOI: 10.1108/17459265200900004 (opens in new tab) Ecstasy MDMA Context archaeology Harm reduction +4